Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: A study from the Intergruppo Italiano Linfomi

Teodoro Chisesi, Monica Bellei, Stefano Luminari, Antonella Montanini, Luigi Marcheselli, Alessandro Levis, Paolo Gobbi, Umberto Vitolo, Caterina Stelitano, Vincenzo Pavone, Francesco Merli, Marina Liberati, Luca Baldini, Roberto Bordonaro, Emanuela Anna Pesce, Massimo Federico

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine, doxorubicin, and vindesine (CAD) (MOPP/EBV/CAD [MEC]) for the initial treatment of advanced-stage Hodgkin's lymphoma to select which regimen would best support a reduced radiotherapy program (limited to two or fewer sites of either previous bulky or partially remitting disease). Superiority of ABVD and MEC to StV was demonstrated. We report analysis of long-term outcome and toxicity. Patients and Methods: Patients with stage IIB, III, or IV were randomly assigned among six cycles of ABVD, three cycles of StV, and six cycles of MEC; radiotherapy was administered in 76, 71, and 50 patients in the three arms, respectively. Results: Currently, the median follow-up is 86 months; in the prolonged observation period, eight additional failures, including two relapses, both in the StV arm, and six additional deaths in complete response were recorded. The 10-year overall survival rates were 87%, 80%, and 78% for ABVD, MEC, and StV, respectively (P = .4). The 10-year failure-free survival was 75%, 74%, and 49% in the ABVD, MEC, and StV arms, respectively (P <.001). The 10-year disease-free survival of patients treated or not with radiotherapy (RT) showed no difference for ABVD or MEC (85% v 80% and 93% v 68%), and a statistically significant difference for StV (76% v 33%; P = .004). No significant long-term toxicity was recorded. Conclusion: The long-term analysis confirmed ABVD and MEC superiority to StV. The use of RT after StV was established as mandatory. ABVD is still to be considered as the standard treatment with a good balance between efficacy and toxicity.

Original languageEnglish
Pages (from-to)4227-4233
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number32
DOIs
Publication statusPublished - Nov 10 2011

Fingerprint

Procarbazine
Mechlorethamine
Vinblastine
Bleomycin
Vincristine
Prednisone
Human Herpesvirus 4
Hodgkin Disease
Radiotherapy
Doxorubicin
Vindesine
Lomustine
Dacarbazine
Etoposide
Disease-Free Survival
Survival Rate
Observation
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma : A study from the Intergruppo Italiano Linfomi. / Chisesi, Teodoro; Bellei, Monica; Luminari, Stefano; Montanini, Antonella; Marcheselli, Luigi; Levis, Alessandro; Gobbi, Paolo; Vitolo, Umberto; Stelitano, Caterina; Pavone, Vincenzo; Merli, Francesco; Liberati, Marina; Baldini, Luca; Bordonaro, Roberto; Pesce, Emanuela Anna; Federico, Massimo.

In: Journal of Clinical Oncology, Vol. 29, No. 32, 10.11.2011, p. 4227-4233.

Research output: Contribution to journalArticle

Chisesi, Teodoro ; Bellei, Monica ; Luminari, Stefano ; Montanini, Antonella ; Marcheselli, Luigi ; Levis, Alessandro ; Gobbi, Paolo ; Vitolo, Umberto ; Stelitano, Caterina ; Pavone, Vincenzo ; Merli, Francesco ; Liberati, Marina ; Baldini, Luca ; Bordonaro, Roberto ; Pesce, Emanuela Anna ; Federico, Massimo. / Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma : A study from the Intergruppo Italiano Linfomi. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 32. pp. 4227-4233.
@article{3b7b10d69bcb4a9db10c2eb1d970408d,
title = "Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: A study from the Intergruppo Italiano Linfomi",
abstract = "Purpose: The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine, doxorubicin, and vindesine (CAD) (MOPP/EBV/CAD [MEC]) for the initial treatment of advanced-stage Hodgkin's lymphoma to select which regimen would best support a reduced radiotherapy program (limited to two or fewer sites of either previous bulky or partially remitting disease). Superiority of ABVD and MEC to StV was demonstrated. We report analysis of long-term outcome and toxicity. Patients and Methods: Patients with stage IIB, III, or IV were randomly assigned among six cycles of ABVD, three cycles of StV, and six cycles of MEC; radiotherapy was administered in 76, 71, and 50 patients in the three arms, respectively. Results: Currently, the median follow-up is 86 months; in the prolonged observation period, eight additional failures, including two relapses, both in the StV arm, and six additional deaths in complete response were recorded. The 10-year overall survival rates were 87{\%}, 80{\%}, and 78{\%} for ABVD, MEC, and StV, respectively (P = .4). The 10-year failure-free survival was 75{\%}, 74{\%}, and 49{\%} in the ABVD, MEC, and StV arms, respectively (P <.001). The 10-year disease-free survival of patients treated or not with radiotherapy (RT) showed no difference for ABVD or MEC (85{\%} v 80{\%} and 93{\%} v 68{\%}), and a statistically significant difference for StV (76{\%} v 33{\%}; P = .004). No significant long-term toxicity was recorded. Conclusion: The long-term analysis confirmed ABVD and MEC superiority to StV. The use of RT after StV was established as mandatory. ABVD is still to be considered as the standard treatment with a good balance between efficacy and toxicity.",
author = "Teodoro Chisesi and Monica Bellei and Stefano Luminari and Antonella Montanini and Luigi Marcheselli and Alessandro Levis and Paolo Gobbi and Umberto Vitolo and Caterina Stelitano and Vincenzo Pavone and Francesco Merli and Marina Liberati and Luca Baldini and Roberto Bordonaro and Pesce, {Emanuela Anna} and Massimo Federico",
year = "2011",
month = "11",
day = "10",
doi = "10.1200/JCO.2010.30.9799",
language = "English",
volume = "29",
pages = "4227--4233",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "32",

}

TY - JOUR

T1 - Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma

T2 - A study from the Intergruppo Italiano Linfomi

AU - Chisesi, Teodoro

AU - Bellei, Monica

AU - Luminari, Stefano

AU - Montanini, Antonella

AU - Marcheselli, Luigi

AU - Levis, Alessandro

AU - Gobbi, Paolo

AU - Vitolo, Umberto

AU - Stelitano, Caterina

AU - Pavone, Vincenzo

AU - Merli, Francesco

AU - Liberati, Marina

AU - Baldini, Luca

AU - Bordonaro, Roberto

AU - Pesce, Emanuela Anna

AU - Federico, Massimo

PY - 2011/11/10

Y1 - 2011/11/10

N2 - Purpose: The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine, doxorubicin, and vindesine (CAD) (MOPP/EBV/CAD [MEC]) for the initial treatment of advanced-stage Hodgkin's lymphoma to select which regimen would best support a reduced radiotherapy program (limited to two or fewer sites of either previous bulky or partially remitting disease). Superiority of ABVD and MEC to StV was demonstrated. We report analysis of long-term outcome and toxicity. Patients and Methods: Patients with stage IIB, III, or IV were randomly assigned among six cycles of ABVD, three cycles of StV, and six cycles of MEC; radiotherapy was administered in 76, 71, and 50 patients in the three arms, respectively. Results: Currently, the median follow-up is 86 months; in the prolonged observation period, eight additional failures, including two relapses, both in the StV arm, and six additional deaths in complete response were recorded. The 10-year overall survival rates were 87%, 80%, and 78% for ABVD, MEC, and StV, respectively (P = .4). The 10-year failure-free survival was 75%, 74%, and 49% in the ABVD, MEC, and StV arms, respectively (P <.001). The 10-year disease-free survival of patients treated or not with radiotherapy (RT) showed no difference for ABVD or MEC (85% v 80% and 93% v 68%), and a statistically significant difference for StV (76% v 33%; P = .004). No significant long-term toxicity was recorded. Conclusion: The long-term analysis confirmed ABVD and MEC superiority to StV. The use of RT after StV was established as mandatory. ABVD is still to be considered as the standard treatment with a good balance between efficacy and toxicity.

AB - Purpose: The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine, doxorubicin, and vindesine (CAD) (MOPP/EBV/CAD [MEC]) for the initial treatment of advanced-stage Hodgkin's lymphoma to select which regimen would best support a reduced radiotherapy program (limited to two or fewer sites of either previous bulky or partially remitting disease). Superiority of ABVD and MEC to StV was demonstrated. We report analysis of long-term outcome and toxicity. Patients and Methods: Patients with stage IIB, III, or IV were randomly assigned among six cycles of ABVD, three cycles of StV, and six cycles of MEC; radiotherapy was administered in 76, 71, and 50 patients in the three arms, respectively. Results: Currently, the median follow-up is 86 months; in the prolonged observation period, eight additional failures, including two relapses, both in the StV arm, and six additional deaths in complete response were recorded. The 10-year overall survival rates were 87%, 80%, and 78% for ABVD, MEC, and StV, respectively (P = .4). The 10-year failure-free survival was 75%, 74%, and 49% in the ABVD, MEC, and StV arms, respectively (P <.001). The 10-year disease-free survival of patients treated or not with radiotherapy (RT) showed no difference for ABVD or MEC (85% v 80% and 93% v 68%), and a statistically significant difference for StV (76% v 33%; P = .004). No significant long-term toxicity was recorded. Conclusion: The long-term analysis confirmed ABVD and MEC superiority to StV. The use of RT after StV was established as mandatory. ABVD is still to be considered as the standard treatment with a good balance between efficacy and toxicity.

UR - http://www.scopus.com/inward/record.url?scp=81155151828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155151828&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.30.9799

DO - 10.1200/JCO.2010.30.9799

M3 - Article

C2 - 21990405

AN - SCOPUS:81155151828

VL - 29

SP - 4227

EP - 4233

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 32

ER -